Figure 1.

Schematic illustration of the use of induced pluripotent stem (iPS) cells in relation to Alzheimer’s disease (AD). (A) iPS cells are derived from a skin biopsy from an AD patient and differentiated into neural progenitor cells and neurons; (B) In familial cases, the disease-causing mutation can be corrected by gene-editing of the iPS cells, and neural progenitor cells and neurons can be used for research and drug screening; (C) The patients can in the long run benefit from these activities by cell therapy, better diagnostic procedures, customized treatments and novel medical approaches.